• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫失调、多内分泌腺病、肠病、X连锁综合征(IPEX)以及Foxp3在人类调节性T细胞发育和功能中的作用。

IPEX and the role of Foxp3 in the development and function of human Tregs.

作者信息

Le Bras Séverine, Geha Raif S

机构信息

Division of Immunology, Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA.

出版信息

J Clin Invest. 2006 Jun;116(6):1473-5. doi: 10.1172/JCI28880.

DOI:10.1172/JCI28880
PMID:16741571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1464917/
Abstract

Genetic defects in the transcription factor forkhead box protein P3 (Foxp3) cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX). IPEX is thought to be due to a defect in naturally arising CD4+ Tregs. In this issue of the JCI, Bacchetta and colleagues demonstrate that patients with IPEX and missense mutations in Foxp3 provide insight into the role of various domains of Foxp3 in the development and function of Tregs (see the related article beginning on page 1713).

摘要

转录因子叉头框蛋白P3(Foxp3)的基因缺陷会导致免疫失调、多内分泌腺病、肠病、X连锁(IPEX)。IPEX被认为是由于天然产生的CD4+调节性T细胞(Tregs)存在缺陷所致。在本期《临床研究杂志》中,巴切塔及其同事证明,患有IPEX且Foxp3存在错义突变的患者有助于深入了解Foxp3各个结构域在Tregs发育和功能中的作用(见第1713页开始的相关文章)。

相似文献

1
IPEX and the role of Foxp3 in the development and function of human Tregs.免疫失调、多内分泌腺病、肠病、X连锁综合征(IPEX)以及Foxp3在人类调节性T细胞发育和功能中的作用。
J Clin Invest. 2006 Jun;116(6):1473-5. doi: 10.1172/JCI28880.
2
Defective regulatory and effector T cell functions in patients with FOXP3 mutations.FOXP3基因突变患者中调节性和效应性T细胞功能缺陷。
J Clin Invest. 2006 Jun;116(6):1713-22. doi: 10.1172/JCI25112.
3
Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome.免疫失调、多内分泌腺病、肠病、X连锁(IPEX)综合征移植后免疫重建及表达叉头框P3(FOXP3)的T细胞的恢复。
Pediatrics. 2008 Apr;121(4):e998-1002. doi: 10.1542/peds.2007-1863. Epub 2008 Mar 3.
4
Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome.免疫失调、多内分泌腺病、肠病、X连锁综合征轻度表型的机制关联。
Clin Gastroenterol Hepatol. 2006 May;4(5):653-9. doi: 10.1016/j.cgh.2005.12.014.
5
Identification of FOXP3-negative regulatory T-like (CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.鉴定免疫失调、多内分泌腺病、肠病、X 连锁综合征患者中 FOXP3 阴性调节性 T 样(CD4(+)CD25(+)CD127(low))细胞。
Clin Immunol. 2011 Oct;141(1):111-20. doi: 10.1016/j.clim.2011.06.006. Epub 2011 Jul 12.
6
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells.免疫失调、多内分泌腺病、肠病、X连锁综合征:叉头框蛋白3突变与调节性T细胞缺乏
J Allergy Clin Immunol. 2007 Oct;120(4):744-50; quiz 751-2. doi: 10.1016/j.jaci.2007.08.044.
7
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity.免疫失调、多内分泌腺病、肠病、X连锁综合征新系列患者的临床和分子特征:叉头框蛋白3表达与疾病严重程度之间的相关性不一致
J Allergy Clin Immunol. 2008 Dec;122(6):1105-1112.e1. doi: 10.1016/j.jaci.2008.09.027. Epub 2008 Oct 25.
8
Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome (IPEX) with intractable diarrhea.伴有顽固性腹泻的免疫失调、多内分泌腺病、肠病、X连锁综合征(IPEX)迟发型
Ital J Pediatr. 2014 Oct 18;40:68. doi: 10.1186/s13052-014-0068-4.
9
A potential screening tool for IPEX syndrome.一种用于免疫失调、多内分泌腺病、肠病、X连锁综合征(IPEX综合征)的潜在筛查工具。
Pediatr Dev Pathol. 2007 Mar-Apr;10(2):98-105. doi: 10.2350/06-07-0130.1.
10
Clinical and molecular characteristics of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China.中国 X 连锁免疫调节、多内分泌腺病、肠病、X 连锁综合征的临床和分子特征。
Scand J Immunol. 2011 Sep;74(3):304-309. doi: 10.1111/j.1365-3083.2011.02574.x.

引用本文的文献

1
Regulatory T cell homeostasis: Requisite signals and implications for clinical development of biologics.调节性 T 细胞稳态:必需的信号及其对生物制剂临床开发的影响。
Clin Immunol. 2023 Jan;246:109201. doi: 10.1016/j.clim.2022.109201. Epub 2022 Dec 5.
2
Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.尼伏鲁单抗联合伊匹单抗致转移性肉瘤样肾细胞癌内分泌病和急性间质性肾炎:病例报告及文献复习。
Front Immunol. 2022 Aug 16;13:993622. doi: 10.3389/fimmu.2022.993622. eCollection 2022.
3
NF-κB in control of regulatory T cell development, identity, and function.NF-κB 调控调节性 T 细胞的发育、特性和功能。
J Mol Med (Berl). 2022 Jul;100(7):985-995. doi: 10.1007/s00109-022-02215-1. Epub 2022 Jun 8.
4
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.肿瘤内表达神经纤毛蛋白-1 的调节性 T 细胞的患病率与癌症患者的预后较差相关。
Sci Transl Med. 2021 Dec 8;13(623):eabf8495. doi: 10.1126/scitranslmed.abf8495.
5
The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.调节性 T 细胞在肺动脉高压中的作用。
Front Immunol. 2021 Aug 19;12:684657. doi: 10.3389/fimmu.2021.684657. eCollection 2021.
6
Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies.同根异果:可视化CTLA-4功能不全、LRBA和DEF6缺陷的当前生物学及临床见解
Front Pediatr. 2021 Apr 28;9:662645. doi: 10.3389/fped.2021.662645. eCollection 2021.
7
Intrahepatic T17/T Cells in Homeostasis and Disease-It's All About the Balance.稳态与疾病中的肝内T17/T细胞——一切皆关乎平衡。
Front Pharmacol. 2020 Oct 2;11:588436. doi: 10.3389/fphar.2020.588436. eCollection 2020.
8
Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells.驯服哨兵:微生物组衍生代谢物与 T 细胞的极化。
Int J Mol Sci. 2020 Oct 19;21(20):7740. doi: 10.3390/ijms21207740.
9
Genetics on early onset inflammatory bowel disease: An update.早发性炎症性肠病的遗传学:最新进展
Genes Dis. 2019 Oct 15;7(1):93-106. doi: 10.1016/j.gendis.2019.10.003. eCollection 2020 Mar.
10
Tolerance regeneration by T regulatory cells in autologous haematopoietic stem cell transplantation for autoimmune diseases.自身造血干细胞移植中调节性T细胞介导的自身免疫病耐受重建
Bone Marrow Transplant. 2020 May;55(5):857-866. doi: 10.1038/s41409-019-0710-2. Epub 2019 Oct 16.

本文引用的文献

1
Defective regulatory and effector T cell functions in patients with FOXP3 mutations.FOXP3基因突变患者中调节性和效应性T细胞功能缺陷。
J Clin Invest. 2006 Jun;116(6):1713-22. doi: 10.1172/JCI25112.
2
FOXP3: of mice and men.FOXP3:人与小鼠的情况
Annu Rev Immunol. 2006;24:209-26. doi: 10.1146/annurev.immunol.24.021605.090547.
3
Imbalance of regulatory T cells in human autoimmune diseases.人类自身免疫性疾病中调节性T细胞的失衡。
Immunology. 2006 Mar;117(3):289-300. doi: 10.1111/j.1365-2567.2005.02317.x.
4
Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice.Foxp3突变小鼠中的过敏性调节异常和高免疫球蛋白E血症
J Allergy Clin Immunol. 2005 Nov;116(5):1106-15. doi: 10.1016/j.jaci.2005.08.046.
5
A function for interleukin 2 in Foxp3-expressing regulatory T cells.白细胞介素2在表达Foxp3的调节性T细胞中的作用。
Nat Immunol. 2005 Nov;6(11):1142-51. doi: 10.1038/ni1263. Epub 2005 Oct 16.
6
Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling.在缺乏白细胞介素2信号传导的情况下,激动剂诱导的CD25 + Foxp3 +调节性T细胞的发育与功能
Nat Immunol. 2005 Nov;6(11):1152-9. doi: 10.1038/ni1264. Epub 2005 Oct 16.
7
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.两种FOXP3亚型在人类CD4+调节性T细胞生成中的作用。
J Clin Invest. 2005 Nov;115(11):3276-84. doi: 10.1172/JCI24685. Epub 2005 Oct 6.
8
Mechanisms of suppression by suppressor T cells.抑制性T细胞的抑制机制。
Nat Immunol. 2005 Apr;6(4):338-44. doi: 10.1038/ni1180.
9
A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.一种适应性良好的调节机制:调节性T细胞的发育与叉头框家族转录因子Foxp3
Nat Immunol. 2005 Apr;6(4):331-7. doi: 10.1038/ni1179.
10
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.叉头转录因子foxp3对调节性T细胞谱系的特异性调控
Immunity. 2005 Mar;22(3):329-41. doi: 10.1016/j.immuni.2005.01.016.